DocGo (NASDAQ:DCGO – Get Free Report) and GeneDx (NASDAQ:WGS – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.
Institutional & Insider Ownership
56.4% of DocGo shares are owned by institutional investors. Comparatively, 61.7% of GeneDx shares are owned by institutional investors. 5.1% of DocGo shares are owned by insiders. Comparatively, 25.2% of GeneDx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for DocGo and GeneDx, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DocGo | 1 | 2 | 2 | 0 | 2.20 |
| GeneDx | 1 | 1 | 7 | 0 | 2.67 |
DocGo currently has a consensus target price of $2.17, suggesting a potential upside of 777.55%. GeneDx has a consensus target price of $90.86, suggesting a potential upside of 31.56%. Given DocGo’s higher possible upside, equities research analysts plainly believe DocGo is more favorable than GeneDx.
Risk & Volatility
DocGo has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, GeneDx has a beta of 1.95, meaning that its stock price is 95% more volatile than the S&P 500.
Valuation & Earnings
This table compares DocGo and GeneDx”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DocGo | $322.20 million | 0.08 | -$182.40 million | ($1.96) | -0.13 |
| GeneDx | $427.54 million | 4.82 | -$21.02 million | ($3.64) | -18.97 |
GeneDx has higher revenue and earnings than DocGo. GeneDx is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares DocGo and GeneDx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DocGo | -65.29% | -40.42% | -24.81% |
| GeneDx | -23.41% | 4.12% | 2.26% |
Summary
GeneDx beats DocGo on 11 of the 13 factors compared between the two stocks.
About DocGo
DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.
About GeneDx
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.
Receive News & Ratings for DocGo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DocGo and related companies with MarketBeat.com's FREE daily email newsletter.
